Dexmedetomidine is a relatively selective alpha-2 adrenergic receptor agonist indicated for:

• Sedation of initially intubated and mechanically ventilated patients in intensive care settings. Dexmedetomidine should be administered by continuous infusion for not more than 24 hours.
• Sedation of non-intubated patients before and/or during surgical and other medical procedures.

Dexmedetomidine is a selective alpha-2 adrenoceptor agonist. By binding to presynaptic alpha-2 receptors, it inhibits the release of norepinephrine, thereby reducing the transmission of pain signals. Activation of postsynaptic alpha-2 receptors decreases sympathetic nervous system activity, leading to reduced blood pressure and heart rate.

Individualize and titrate Dexmeditomidine dosing to desired clinical effect.

Administer Dexmeditomidine using a controlled infusion device.

Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration.

The 200 mcg/50 mL single-use bottles do not require further dilution prior to administration.

For Adult Intensive Care Unit Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour.

For Adult Procedural Sedation: Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour.

Alternative Doses: Recommended for patients over 65 years of age and awake fiberoptic intubation patients.

Co-administration of dexmedetomidine with anesthetics, sedatives, hypnotics, or opioids may enhance their pharmacological effects.

Body as a whole: Fever, hyperpyrexia, hypovolemia, light anesthesia, pain, rigors.

Cardiovascular disorders (general): Blood pressure fluctuations, heart disorders, hypertension, hypotension, myocardial infarction.

Central and peripheral nervous system disorders: Dizziness, headache, neuralgia, neuritis, speech disorder, convulsions.

Gastrointestinal system disorders: Abdominal pain, diarrhea, vomiting, nausea.

Liver and biliary system disorders: Increased gamma-glutamyl transpeptidase, abnormal liver function, hyperbilirubinemia.

Metabolic and nutritional disorders: Acidosis, respiratory acidosis, hyperkalemia, thirst, hypoglycemia.

Psychiatric disorders: Agitation, confusion, delirium, hallucinations, illusions.

Red blood cell disorders: Anemia.

Renal disorders: Increased blood urea nitrogen, oliguria.

Respiratory system disorders: Hypoventilation, hypoxia, pulmonary congestion.

Skin disorders: Increased sweating.

Vascular disorders: Hemorrhage.

Vision disorders: Photopsia, abnormal vision.

Pregnancy Category C.

Continuous monitoring is required during Dexmedetomidine administration.।

Bradycardia, hypotension, and cardiac arrest have been observed.

Miscellaneous sedatives & hypnotics

Store below 30°C, protected from light and moisture. Keep out of reach of children.